4-[N-(aminocarbonyl)-phenylamino]piperidine | 864738-85-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-[N-(aminocarbonyl)-phenylamino]piperidine
• 英文别名: 1-Phenyl-1-piperidin-4-ylurea
• CAS: 864738-85-2
• 化学式: C₁₂H₁₇N₃O
• 分子量: 219.286
• InChiKey: MVISYWCURYLBBD-UHFFFAOYSA-N

物化性质

• 沸点：
  372.3±52.0 °C(Predicted)
• 密度：
  1.174±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.42
• 拓扑面积：
  58.4
• 氢给体数：
  2
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-[N-(aminocarbonyl)-phenylamino]piperidine 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 1-[N²-[N-[[4-[N-(aminocarbonyl)phenylamino]-1-piperidinyl]carbonyl]-3,5-dibromo-D-tyrosyl]-L-lysyl]-4-(4-pyridinyl)piperazine bis(trifluoroacetate)
  参考文献：
  名称：

  Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. 1. Potent and Selective Small Molecule CGRP Antagonists. 1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1- piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine:  The First CGRP Antagonist for Clinical Trials in Acute Migraine

  摘要：

  Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings. Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans. Our novel approach was based on the hypothesis that the release of calcitonin gene-related peptide (CGRP) could play a causative role in migraine headache. Thus we initiated a program aimed at the design and synthesis of small molecule CGRP receptor antagonists. High throughput screening led to the identification of (R)-Tyr-(S)-Lys dipeptide-like compounds that showed weak but unequivocal binding to the human CGRP receptor. Lead optimization afforded highly potent CGRP antagonists, the prototype being compound 19 (BIBN4096). This compound exhibiting a favorable biological profile was selected for initial clinical trials. A proof of concept study indicated that intravenous application of 19 was effective in the treatment of acute migraine headache. This finding strongly supports our initial working hypothesis that CGRP plays an important role in the pathophysiology of migraine.

  DOI：

  10.1021/jm0490641
• 作为产物：
  描述：

  4-苯胺-1-苯甲基哌啶 在 palladium dihydroxide 氢气 、 三氟乙酸 作用下， 以 甲醇 为溶剂， 生成 4-[N-(aminocarbonyl)-phenylamino]piperidine
  参考文献：
  名称：

  Development of Human Calcitonin Gene-Related Peptide (CGRP) Receptor Antagonists. 1. Potent and Selective Small Molecule CGRP Antagonists. 1-[N²-[3,5-Dibromo-N-[[4-(3,4-dihydro-2(1H)-oxoquinazolin-3-yl)-1- piperidinyl]carbonyl]-d-tyrosyl]-l-lysyl]-4-(4-pyridinyl)piperazine:  The First CGRP Antagonist for Clinical Trials in Acute Migraine

  摘要：

  Although the triptans have greatly improved the acute treatment of migraine headache, there are yet many shortcomings. Therefore, new strategies for the treatment of migraine are needed which offer advantages over current therapy, e.g. triptans. Our novel approach was based on the hypothesis that the release of calcitonin gene-related peptide (CGRP) could play a causative role in migraine headache. Thus we initiated a program aimed at the design and synthesis of small molecule CGRP receptor antagonists. High throughput screening led to the identification of (R)-Tyr-(S)-Lys dipeptide-like compounds that showed weak but unequivocal binding to the human CGRP receptor. Lead optimization afforded highly potent CGRP antagonists, the prototype being compound 19 (BIBN4096). This compound exhibiting a favorable biological profile was selected for initial clinical trials. A proof of concept study indicated that intravenous application of 19 was effective in the treatment of acute migraine headache. This finding strongly supports our initial working hypothesis that CGRP plays an important role in the pathophysiology of migraine.

  DOI：

  10.1021/jm0490641

文献信息

• [EN] 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES<br/>[FR] DERIVES DE 6-PHENYLPYRIDYL-2-AMINES
  申请人：PFIZER INC.

  公开号：WO1997036871A1

  公开（公告）日：1997-10-09

  (EN) The present invention relates to certain 6-phenyl-pyridin-2-ylamine derivatives that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system disorders.(FR) La présente invention, qui concerne certains dérivés de 6-phénylpyridyl-2-amines faisant preuve d'une activité d'inhibiteurs du monoxyde d'azote synthétase, concerne aussi des compositions pharmaceutiques contenant de tels dérivés. L'invention concerne également l'utilisation de ces compositions pharmaceutiques pour le traitement et la prévention de troubles du système nerveux central.

  该发明涉及某些6-苯基吡啶-2-基胺衍生物，其表现出一定的一氧化氮合酶（NOS）抑制剂活性，以及包含它们的制药组合物及其在治疗和预防中枢神经系统疾病中的使用。
• 6-phenylpyridyl-2-amine derivatives
  申请人：——

  公开号：US20010034348A1

  公开（公告）日：2001-10-25

  The present invention relates to certain 6-phenyi-pyridin-2-ylamine derivatives that exhibit activity as nitric oxide synthase (NOS) inhibitors, to pharmaceutical compositions containing them and to their use in the treatment and prevention of central nervous system disorders.

  本发明涉及某些6-苯基吡啶-2-胺衍生物，其展示了作为一氧化氮合酶（NOS）抑制剂的活性，以及含有它们的制药组合物和它们在治疗和预防中枢神经系统疾病中的应用。
• NAMPT INHIBITORS
  申请人：AbbVie Inc.

  公开号：US20160184281A1

  公开（公告）日：2016-06-30

  Disclosed are compounds which inhibit the activity of NAMPT, compositions containing the compounds and methods of treating diseases during which NAMPT is expressed.

  本发明涉及抑制NAMPT活性的化合物、含有该化合物的组合物以及治疗NAMPT表达疾病的方法。
• 6-PHENYLPYRIDYL-2-AMINE DERIVATIVES
  申请人：PFIZER INC.

  公开号：EP0891332A1

  公开（公告）日：1999-01-20
• US6235747B1
  申请人：——

  公开号：US6235747B1

  公开（公告）日：2001-05-22